Literature DB >> 17898760

Taking dendritic cells into medicine.

Ralph M Steinman1, Jacques Banchereau.   

Abstract

Dendritic cells (DCs) orchestrate a repertoire of immune responses that bring about resistance to infection and silencing or tolerance to self. In the settings of infection and cancer, microbes and tumours can exploit DCs to evade immunity, but DCs also can generate resistance, a capacity that is readily enhanced with DC-targeted vaccines. During allergy, autoimmunity and transplant rejection, DCs instigate unwanted responses that cause disease, but, again, DCs can be harnessed to silence these conditions with novel therapies. Here we present some medical implications of DC biology that account for illness and provide opportunities for prevention and therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17898760     DOI: 10.1038/nature06175

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  779 in total

1.  Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation.

Authors:  Qing Ma; Dan Li; Roza Nurieva; Rebecca Patenia; Roland Bassett; Wei Cao; Andrei M Alekseev; Hong He; Jeffrey J Molldrem; Michael H Kroll; Richard E Champlin; George E Sale; Vahid Afshar-Kharghan
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-01       Impact factor: 5.742

2.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

Authors:  Eynav Klechevsky; Anne-Laure Flamar; Yanying Cao; Jean-Philippe Blanck; Maochang Liu; Amy O'Bar; Olivier Agouna-Deciat; Peter Klucar; Luann Thompson-Snipes; Sandra Zurawski; Yoram Reiter; A Karolina Palucka; Gerard Zurawski; Jacques Banchereau
Journal:  Blood       Date:  2010-06-07       Impact factor: 22.113

4.  Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity.

Authors:  Hideki Fujita; Mayte Suárez-Fariñas; Hiroshi Mitsui; Juana Gonzalez; Mark J Bluth; Shali Zhang; Diane Felsen; James G Krueger; John A Carucci
Journal:  J Invest Dermatol       Date:  2012-03-08       Impact factor: 8.551

5.  Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant.

Authors:  Jan Ole Kemnade; Mamatha Seethammagari; Priya Narayanan; Jonathan M Levitt; Alison A McCormick; David M Spencer
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

6.  Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines.

Authors:  Eynav Klechevsky; Maochang Liu; Rimpei Morita; Romain Banchereau; Luann Thompson-Snipes; A Karolina Palucka; Hideki Ueno; Jacques Banchereau
Journal:  Hum Immunol       Date:  2009-02-21       Impact factor: 2.850

Review 7.  Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors:  Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

Review 8.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

Review 9.  Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis.

Authors:  Jayshree Mishra; Joseph Drummond; Sohel H Quazi; Satya Sridhar Karanki; J J Shaw; Ben Chen; Narendra Kumar
Journal:  Crit Rev Oncol Hematol       Date:  2012-10-23       Impact factor: 6.312

Review 10.  Immunotherapy in ovarian cancer.

Authors:  Gina M Mantia-Smaldone; Bradley Corr; Christina S Chu
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.